About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Announces Lead Investment in Visionary Anti-Fibrotic Company Blade Therapeutics

New York, New York – June 16, 2016 –DeerfieldManagement Company today announced its lead investment in the visionary anti-fibroticcompany Blade Therapeutics. Blade Therapeutics is developing cutting edge therapies to treat patients with diverse fibrotic diseasesfor which there are currently no remedies. The proceeds from the $45 millionSeries B financing will be used to advance the selection and development of a leadmolecule.

Blade Therapeutics exploits novel targetbiology to halt the progression of fibrosis. The technology is licensed fromJohns Hopkins University School of Medicine and is based on the research from thelaboratory of Harry (“Hal”) Dietz, M.D., the Victor A. McKusick Professor ofGenetics in the Institute of Genetic Medicine at Johns Hopkins University School of Medicine.

“Weare excited to support the ground-breaking science developed at Johns Hopkins.  It truly has the potential to change the courseof fibrosis and provide disease altering therapies to patients,” stated WilliamSlattery, partner at Deerfield Management.

“Fibrosis,in its many forms, is a clear unmet need and affects a diverse number ofpatients,” commented Cameron Wheeler, principal at Deerfield Management Company. “The chemistry and biology developed bythe Blade team has created a new path to a potential cure.”

WendyeRobbins, MD and CEO of Blade said “We are looking forward to having Deerfieldas an investor in Blade. Deerfield has shown an ability to provide supportbeyond capital which we believe will leverage our capabilities as Blade growsboth scientifically and operationally. We are also excited to welcome PfizerVentures, Bristol Meyers Squibb, and Novartis to the syndicate. We believe thatwith the leadership of this premier team of investors in addition to ourexisting shareholders we will be in a position to build the leading fibrosiscompany.”

About Blade Therapeutics

Blade Therapeutics is a privatebiopharmaceutical company revolutionizing the treatment of fibrotic disease.Blade is exploiting novel target biology to halt the progression of fibroticdisease. The company is committed to building the leading company in anti-fibrotic drug discovery anddevelopment.  Blade began operations inthe third quarter of 2015 with a license to ground-breaking research from Harry(“Hal”) Dietz, Johns HopkinsUniversity School of Medicine and investment from MPM Capital. The company’s talentedand dedicated team of scientists are committed to the discovery and developmentof novel therapies that can modify the course of multiple fibroticdiseases.  Please visit for more information.

About Deerfield

Deerfield is an investment management firmcommitted to advancing healthcare through investment, information andphilanthropy.

For more information, please visit


DeerfieldManagement Company
Karen Heidelberger, 212-692-7140
[email protected]